Eden vs Henry Meds: Compounded GLP-1 Compared
Eden and Henry Meds are two of the most established compounded GLP-1 platforms. Eden differentiates with brand-name access (Wegovy, Zepbound, Ozempic, Mounjaro) sitting alongside its compounded line; Henry Meds emphasizes oral-dissolving and sublingual semaglutide options for needle-averse patients.
Eden
Flat upfront pricing with the same dose-equal cost across both compounded and brand-name GLP-1s.
Henry Meds
Affordable subscription telehealth with one of the largest compounded formularies in the industry.
| Attribute | Eden | Henry Meds |
|---|---|---|
| Program Fee | No membership fee | Included in monthly plan |
| Medication From | From $129/mo | From $129/mo |
| Editor Score | 4.5 / 5 | 4.6 / 5 |
| Primary Category | GLP-1 Weight Loss | GLP-1 Weight Loss |
| FDA Brand-Name Access | Ozempic, Wegovy, Zepbound, Mounjaro | KYZATREX |
| Compounded Options | 2 compounds | 9 compounds |
| Adjacent Categories | GLP-1 Weight Loss, Women's Health & HRT, Hair Loss, Skincare, Peptide Therapy, Longevity & NAD+ | GLP-1 Weight Loss, TRT & Men's Hormones, Women's Health & HRT, Erectile Dysfunction |
What the Studies Actually Show
Compounded GLP-1 medications are not FDA-approved; they are prepared by 503A or 503B compounding pharmacies under state and federal regulation. Efficacy is inferred from the underlying active ingredient (semaglutide or tirzepatide) studied in pivotal Phase 3 trials. Sublingual and oral-dissolving formulations have less published bioequivalence data than injectable forms.
| Endpoint | Eden | Henry Meds |
|---|---|---|
| Underlying active ingredients | Semaglutide (compounded + brand) and tirzepatide (compounded + brand) | Semaglutide (injectable + sublingual) and tirzepatide (injectable) |
| Mean weight loss in pivotal trials of the active ingredients1,2 | Semaglutide 2.4 mg: −14.9% over 68 weeks · Tirzepatide 15 mg: −20.9% over 72 weeks | Same — efficacy depends on the molecule, not the brand |
| Sublingual semaglutide bioavailability3 | Not offered | Limited published bioequivalence data versus injectable |
| Brand-name GLP-1 access | Wegovy, Zepbound, Ozempic, Mounjaro available as eligible upgrades | Compounded only at present |
| Adjacent formulary (non-GLP-1) | Limited | ED, TRT, hair loss, and women's hormones available on the same platform |
Note on sublingual semaglutide bioavailabilitySublingual and oral-dissolving routes are convenient but have weaker pharmacokinetic evidence than the once-weekly injection studied in the STEP and SUSTAIN trials.
The Verdict
Choose Eden if you want the option to upgrade to FDA-approved brand-name GLP-1 without changing platforms. Choose Henry Meds for the broader compounded formulary, including ED and TRT, plus oral-dissolving semaglutide.
- STEP 1 Trial — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SURMOUNT-1 Trial — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- FDA Statement on Compounded GLP-1 Drugs (2024) · FDA. Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss. U.S. Food and Drug Administration.
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.